An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis
Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare,
progressive, fatal multi-systemic disease, autosomal dominantly inherited with …
progressive, fatal multi-systemic disease, autosomal dominantly inherited with …
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis.
P Milani, R Mussinelli, S Perlini… - Expert Opinion on …, 2019 - europepmc.org
Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare,
progressive, fatal multi-systemic disease, autosomal dominantly inherited with …
progressive, fatal multi-systemic disease, autosomal dominantly inherited with …
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis
P Milani, R Mussinelli, S Perlini… - Expert opinion on …, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare,
progressive, fatal multi-systemic disease, autosomal dominantly inherited with …
progressive, fatal multi-systemic disease, autosomal dominantly inherited with …
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis
P Milani, R Mussinelli, S Perlini, G Palladini… - EXPERT OPINION ON …, 2019 - iris.unipv.it
Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare,
progressive, fatal multi-systemic disease, autosomal dominantly inherited with …
progressive, fatal multi-systemic disease, autosomal dominantly inherited with …